Exchange: NYSEMkt·Updated 07:30 PM EDT

OSTX Earnings

Latest Earnings Results: Q2 '26

Reported: Aug 14

Estimated EPS

-$0.18

Reported EPS

-$0.20

Surprise

-8.7%

Estimated Rev

$0M

Reported Rev

---

Surprise

---

OS Therapies reported a net loss of $19.0 million for the six months ended June 30, 2026, with research and development expenses totaling $13.4 million during the same period.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '26
-$0.14
--
--
N/A
Q2 '26
-$0.18
-$0.20
-8.70%
MISSED
Q1 '26
-$0.20
-$0.27
-33.66%
MISSED
Q4 '25
-$0.25
--
--
N/A
Q3 '25
-$0.16
-$0.21
-31.25%
MISSED

Advertisement|Remove ads.